Disc Medicine (IRON) Income towards Parent Company (2020 - 2026)
Disc Medicine (IRON) reported Income towards Parent Company of -$63.5 million for Q1 2026, down 86.81% year-over-year from -$481.2 million in Q1 2025, and down 4.26% on a QoQ basis from -$60.9 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Income towards Parent Company data on file, last reported at -$63.5 million in Q1 2026.
- Quarterly Income towards Parent Company fell 86.81% year-over-year to -$63.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$241.9 million (down 107.96% YoY) and the FY2025 annual result came in at -$212.5 million, down 94.33% from the prior year.
- Income towards Parent Company eased to -$63.5 million in Q1 2026 per IRON's latest filing, from -$60.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$9.6 million in Q2 2022 and bottomed at -$63.5 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$26.3 million (2024), against an average of -$29.9 million.
- Peak annual rise in Income towards Parent Company reached 46.27% in 2022, while the deepest fall reached 161.83% in 2022.
- Tracing IRON's Income towards Parent Company over 5 years: stood at -$11.2 million in 2022, then tumbled by 109.41% to -$23.5 million in 2023, then slipped by 25.1% to -$29.5 million in 2024, then plunged by 106.61% to -$60.9 million in 2025, then dropped by 4.26% to -$63.5 million in 2026.
- Per Business Quant, the three latest IRON Income towards Parent Company figures stand at -$63.5 million (Q1 2026), -$60.9 million (Q4 2025), and -$62.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.45 Mn |
| Dec 31, 2025 | -60.86 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.46 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.29 Mn |
| Mar 31, 2024 | -26.95 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.95 Mn |
| Mar 31, 2023 | -22.78 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -16.44 Mn |
| Mar 31, 2021 | -18.34 Mn |
| Dec 31, 2020 | -812,495.00 |
| Sep 30, 2020 | -499,411.00 |
| Jun 30, 2020 | -6.77 Mn |
| Mar 31, 2020 | -9.75 Mn |